Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Profusa Inc (PFSA)

Profusa Inc (PFSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,699
  • Shares Outstanding, K 1,359
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,710 K
  • EBIT $ -24 M
  • EBITDA $ -24 M
  • 60-Month Beta 0.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4101 +197.49%
on 03/19/26
2.2500 -45.78%
on 04/06/26
+0.3298 (+37.05%)
since 03/06/26
3-Month
0.4101 +197.49%
on 03/19/26
9.8475 -87.61%
on 01/16/26
-6.1300 (-83.40%)
since 01/08/26

Most Recent Stories

More News
Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform

Company secures scalable multi-omics diagnostics platform and launches Mayo Clinic partnership adding to Lumee real-time biochemistry monitoring platform to advance pancreatic cancer applications BERKELEY,...

PFSA : 1.2200 (-2.40%)
Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering

After Reevaluating its Near-term Capital Needs Given the Recent Changes in its Projected 2026 Revenue and Mayo Collaboration, the Company Determined that a $15 Million Offering is Not Required to Achieve...

PFSA : 1.2200 (-2.40%)
Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance

With strong underlying market demand, European distributor and expert physician customer purchase orders are being received by the Company as its 2026 revenue guidance range increases to $1.5 million -...

PFSA : 1.2200 (-2.40%)
Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies

Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product Seeking to develop and commercialize new...

PFSA : 1.2200 (-2.40%)
Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies

Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product Seeking to develop and commercialize new...

PFSA : 1.2200 (-2.40%)
Profusa Announces 1-for-75 Reverse Stock Split

BERKELEY, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology...

PFSA : 1.2200 (-2.40%)
Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026

Study conducted at US sites evaluates Lumee TM in peripheral artery disease (PAD) patients BERKELEY, Calif, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”)...

PFSA : 1.2200 (-2.40%)
Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue

Research-use-only offerings are commercially available, enabling immediate product and service revenue generation Targets the global CRO market of $47.9 billion in 2025 and growing at 7% CAGR ...

PFSA : 1.2200 (-2.40%)
Profusa Adds Leading Greek Vascular Surgeon to Customer Base

Dr. Theodosios Bisdas is a renowned vascular surgeon and Head of Clinic of Vascular Surgery at the Athens Medical Center BERKELEY, Calif, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa”...

PFSA : 1.2200 (-2.40%)
Profusa Bolsters European Commercial Network with New French Distributor, MedSell

MedSell commercializes Lumee™ Oxygen tissue monitoring in France, building upon distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia, to now...

PFSA : 1.2200 (-2.40%)

Business Summary

Profusa Inc. is a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry. Profusa Inc., formerly known as NorthView Acquisition Corp., is based in BERKELEY, Calif.

See More

Key Turning Points

3rd Resistance Point 1.6567
2nd Resistance Point 1.4933
1st Resistance Point 1.3567
Last Price 1.2200
1st Support Level 1.0567
2nd Support Level 0.8933
3rd Support Level 0.7567

See More

52-Week High 180.0000
Fibonacci 61.8% 111.3967
Fibonacci 50% 90.2050
Fibonacci 38.2% 69.0134
Last Price 1.2200
52-Week Low 0.4101

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.